Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Jose Antonio Pérez-Simón, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, Claudia Sargas, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Júlia Morán Sánchez, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordonez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, Jorge Labrador, Pau Montesinos

Blood (2024) 144 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2024-205064

Published: 2024

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2024-205181

Published: 2024

Journal Articles

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2024-201264

Published: 2024

Journal Articles

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 6135.

https://doi.org/10.1182/blood-2024-201316

Published: 2024

Journal Articles

RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

Blood (2024) 144 (Supplement 1): 3583.1.

https://doi.org/10.1182/blood-2024-201734

Published: 2024

Journal Articles

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Blood (2024) 144 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2024-201407

Published: 2024

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study

Ami J. Shah, José Luis López Lorenzo, Julián Sevilla, Susana Navarro, Lucía Llanos, Begoña Pérez de Camino Gaisse, Sol Sanchez, Josune Zubicaray, Bert Glader, May Chien, Oscar Quintana Bustamante, Miriam Zeini, Grace Choi, Eileen Nicoletti, Gayatri R. Rao, Maria Grazia Roncarolo, Juan A. Bueren, Jonathan D. Schwartz, José C. Segovia

Blood (2022) 140 (Supplement 1): 4902–4903.

https://doi.org/10.1182/blood-2022-170948

Published: 2022

Journal Articles

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients

Blood (2021) 138 (Supplement 1): 563.

https://doi.org/10.1182/blood-2021-148161

Published: 2021

Journal Articles

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Blood (2021) 138 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2021-150992

Published: 2021

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-137246

Published: 2020

Journal Articles

Correction of the Energetic Defects in Pyruvate Kinase Deficiency through Genome Editing in Hematopoietic Stem and Progenitor Cells

Sara Fañanas-Baquero, Oscar Quintana Bustamante, PhD, Daniel P. Dever, PhD, Omaira Alberquilla, Rebeca Sanchez-Dominguez, PhD, Joab Camarena, BS, Rolf Turk, José Luis López Lorenzo, MD, Paola Bianchi, BSc, PhD, Mark Behlke, MD PhD, Juan A Bueren, PhD, Matt Porteus, MD PhD, José C Segovia, PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-139117

Published: 2020

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Juan Manuel Alonso Dominguez, MD PhD MSc, Rodrigo Iñiguez Garcia, MD, Susana Olmedillas, PhD, Rocio N Salgado, PhD, Tamara Castaño, MD, Carlos Blas, MD, Diego Velasco Rodrgiguez, MD PhD, Gala Vega, MD, Jose Luis Lopez Lorenzo, MD, Pilar Giraldo, PhD, Joaquin Martinez Lopez, MD PhD, Pilar Llamas, MDPhD, Mireia Atance, Arantxa Garcías Raso

Blood (2017) 130 (Supplement 1): 2891.

https://doi.org/10.1182/blood.V130.Suppl_1.2891.2891

Published: 2017

Journal Articles

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

Juan Manuel Alonso Dominguez, MD PhD MSc, Alicia Arenas, PhD, Pilar Llamas, MDPhD, Diego Velasco, Aránzazu García-Raso, PhD, Jose Luis Lopez Lorenzo, MD, Mireia Atance, Rocio N Salgado, PhD, Joaquin Martinez Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 5245.

https://doi.org/10.1182/blood.V130.Suppl_1.5245.5245

Published: 2017

NARROW

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Correction of the Energetic Defects in Pyruvate Kinase Deficiency through Genome Editing in Hematopoietic Stem and Progenitor Cells

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only